Bill · S. 3751· Senate(119-S-3751)
Prescription Drug Supply Chain Pricing Transparency Act
- Introduced
- 1/29/2026
- Last activity
- 1/29/2026 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Michael Bennet
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
This bill, titled the "Prescription Drug Supply Chain Pricing Transparency Act," directs the Comptroller General of the United States to perform a specific study. The study focuses on compensation and payment structures tied to prescription drug prices within the retail supply chain. It aims to examine how various intermediaries, such as pharmacy benefit managers and drug wholesalers, are compensated. The Comptroller General is tasked with looking at business models, potential conflicts of interest, and pricing trends. Finally, a report including recommendations for legislation or administrative action must be submitted to Congress within two years.
Yes· 3 of 8
Does this make what the government does easier for the public to see?+4
The bill increases transparency by requiring a formal study and report on the compensation structures within the prescription drug supply chain.
Does this lower the price of prescription medicines?+3
The study seeks to understand and provide recommendations to address compensation structures that may drive up drug prices.
Does this give people more protection from unfair business practices?+3
The study aims to identify conflicts of interest where compensation structures might favor higher-priced drugs, which could protect consumers from inflated costs.
The opposite
Would business owners be better off under this?-2
The study investigates the compensation and business models of drug wholesalers and pharmacy benefit managers.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Transparency of Drug Pricing: By requiring a study on the type, magnitude, and prevalence of compensation structures related to drug prices, the bill seeks to understand how money moves between intermediaries like pharmacy benefit managers, wholesalers, and manufacturers (Section 2, subsection (e)(1)(A)).
-
Identification of Conflicts of Interest: The study is designed to look for potential conflicts of interest, such as whether fees set as a percentage of a drug's price might be used to favor drugs with higher prices (Section 2, subsection (e)(1)(D)).
-
Insight into Pricing Trends: The bill calls for an analysis of patterns and trends in price-based compensation structures over time and across different market segments, including Medicaid (Section 2, subsection (e)(1)(E)).
-
Actionable Recommendations: The Comptroller General is required to provide recommendations for legislation or administrative action based on the study's findings (Section 2, subsection (e)(2)).
Potential Negative Impacts for People
- No negative impacts are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+2Good For Middle Class Households+2Good For Retirees+2Good For Seniors+2Good For Business Owners-2
- Healthcare
- Reduces Prescription Drug Costs+3Increases Medicaid Funding+2
- Governance And Ideology
- Improves Government Transparency+4
- Economy And Finance
- Improves Consumer Protection+3
- 1/29/2026
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
James LankfordRepublican · Oklahoma